Print the page
Increase font size
Biogen Breaks Through 5-Year Stalemate

Posted June 09, 2021

Biogen Breaks Through 5-Year Stalemate

In response to my friend’s unemployment insurance predicament, a reader says: “Typical government thinking. They penalize a small business that did the right thing by keeping all their employees working.

“The federal government creates a problem, and then asks others to pay for it.”

Another reader references the American Rescue Plan…

“I found this most interesting since the whole purpose of the federal government stimulus money to states was to cover these UI costs.

“So what did states do with the money if they didn't apply it to the unemployment fund as stipulated? I think Maryland has some ‘splainin to do, don't you?”

Indeed, reader. We’ll cover that Friday…

Send your opinions to, TheRundownFeedback@StPaulResearch.com.

Your Rundown for Wednesday, June 9, 2021…

Biogen’s Big Step Forward…

“This could be a key moment for the biotech sector,” says our chief market analyst Greg Guenthner.

Of course, Greg’s talking about the market’s big mover Monday -- Biogen Inc. -- and BIIB’s breakneck ascent, jumping more than 50%, after the company received FDA approval for its Alzheimer drug Aduhelm.

“Results from clinical trials of Aduhelm were mixed,” Reuters says, “but the drug was shown to reduce amyloid beta plaques in the brain, which is likely to benefit patients.”

To give an idea how important this drug is, there hasn’t been an approved Alzheimer’s treatment since 2003… for a disease that’s the sixth leading cause of death in the U.S.

"We've not had a disease modifying therapy approved ever," says Alzheimer’s specialist Dr. Ronald Petersen of the Mayo Clinic. But he warns: "This is not a cure. It's hoped that this will slow the progression of the disease."

A step forward in the fight against Alzheimer’s Disease might be a step forward for an entire stock sector…

“This could be a key moment for the biotech sector,” Greg says, “especially when you consider that BIIB stock has gone essentially nowhere since 2015!

“BIIB has been dead money for more than five years,” he adds. “In fact, biotech as a sector has been a laggard ever since it flamed out during the stealth bear market of 2015–16.”

Greg’s takeaway? “Perhaps we finally see a sustained post-pandemic run in biotech. It’s long overdue -- and worth watching closely for trading opportunities moving forward.”

Market Rundown for Wednesday, June 9, 2021

The S&P 500 Index is up 6.5 points to 4,232… approaching record highs.

Oil is up 0.5% to $70.41 for a barrel of West Texas Intermediate.

Gold is up $3.30 to $1,898.10 per ounce.

Bitcoin is up 6.45% to $34,969.50.

Send your comments and questions to, TheRundownFeedback@StPaulResearch.com.

We’ll be back Friday; have a good one!

For The Rundown,

Aaron Gentzler

Aaron Gentzler
Editor, The Rundown
TheRundownFeedback@StPaulResearch.com

The Most Important Rundown You’ll Read This Year

The Most Important Rundown You’ll Read This Year

Posted October 12, 2026

By Matt Insley

Jim Rickards warns that soaring AI stock prices rest on shaky financial foundations. Enrique Abeyta raises another possibility: AI could become too big to fail.
No Gamble, No Future

No Gamble, No Future

Posted October 09, 2026

By Matt Insley

The NFL takes its fight against Kalshi to the Supreme Court as prediction markets threaten traditional sportsbooks and Gen Z embraces gambling as investing.
Bloodshed Draws Rubberneckers

Bloodshed Draws Rubberneckers

Posted October 07, 2026

By Emily Clancy

Student protests are sweeping France while $10 diesel adds to the pressure. Here’s why Europe’s growing energy squeeze matters to Americans.
After SaaS, Private Credit Bets on AI

After SaaS, Private Credit Bets on AI

Posted October 05, 2026

By Matt Insley

Amazon wants to turn $8 billion of Nvidia chips into cash as private credit prepares to finance up to $1 trillion of the AI buildout.
Jim Rickards: 33 Days to Midterms

Jim Rickards: 33 Days to Midterms

Posted October 01, 2026

By Matt Insley

With 33 days until the midterms, Jim Rickards looks past the headline polls to the races and voters that could determine control of Congress.
“A Closet Liberal, IMO.”

“A Closet Liberal, IMO.”

Posted September 30, 2026

By Matt Insley

Rundown readers weigh in on Flock cameras, Pete Hegseth, Trump’s $5,000 tariff dividend and Jack Ma — with plenty of disagreement along the way.